ArticleCancer discovery2022
Sex-Biased
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 85 citations in OpenAlex.
- Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.Leukemia · 2026Trial
- Review
- Clinico-hematopathologic and Genetic Characteristics of Korean Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Single-Center Cohort Study.Annals of laboratory medicine · 2026Article
- Dysregulation of U12-Type Splicing in Lupus Neutrophils.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Loss of Chromosome Y Associates With Altered Immune Cell Trajectories and X-Inactivation Features.Aging cell · 2026Article
- Contribution of a specific panel by flow cytometry for the differential diagnosis of plasmacytoid dendritic cell neoplasms.Annals of hematology · 2026Article
- RNA Splicing as a Therapeutic Target in Cancer.Annual review of pharmacology and toxicology · 2026Review
- Diagnostic Challenges in a Young Man with a Suspected Mast Cell Disorder, Dysplastic Bone Marrow Morphology, and aHematology reports · 2025Article
- Dysregulation of U12-Type Splicing in Lupus Neutrophils.bioRxiv : the preprint server for biology · 2025Article
- Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications.Current hematologic malignancy reports · 2025Review
- Acute myeloid leukemia with plasmacytoid dendritic cell proliferation: A case report and literature review.Oncology letters · 2025Article
- Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.Oncotarget · 2025Article
- Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.JCI insight · 2024Article
- BPDCN: state of the art.Hematology. American Society of Hematology. Education Program · 2024Review
- Article
- Radiation Therapy for Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Review of the Literature.Current oncology (Toronto, Ont.) · 2024Review
- Advancing the understanding and management of blastic plasmacytoid dendritic cell neoplasm: Insights from recent case studies.World journal of clinical cases · 2024Article
- Acute myeloid leukemia: does sex matter?Leukemia · 2024Review
- Alternative Splicing: A Potential Therapeutic Target in Hematological Malignancies.Hematology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 11 institutions in 5 countries.
Katsuhiro TogamiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-8422-0008
Sun Sook ChungDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7340-3359
Vikas MadanCancer Science Institute of Singapore, National University of Singapore, Singapore.ORCID 0000-0001-7876-624X
Christopher A G BoothDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3841-6637
Christopher M KenyonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-2991-328X
Lucia Cabal-HierroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Justin TaylorHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4407-6325
Sunhee S KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-6477-5679
Gabriel K GriffinDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Mahmoud GhandiBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0003-1897-2265
Jia LiCancer Science Institute of Singapore, National University of Singapore, Singapore.
Yvonne Y LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Fanny Angelot-DelettreUniversité Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Sabeha BiichleUniversité Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Michael SeilerH3 Biomedicine, Cambridge, Massachusetts.
Silvia BuonamiciH3 Biomedicine, Cambridge, Massachusetts.
Scott B LovitchDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-9013-0105
Abner LouissaintDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Elizabeth A MorganDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5880-9337
Fabrice JardinInserm U1245, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France.ORCID 0000-0002-6804-7943
Pier Paolo PiccalugaDepartment of Experimental, Diagnostic, and Specialty Medicine, Bologna University Medical School, Bologna, Italy.ORCID 0000-0002-9432-0595
David M WeinstockDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8724-3907
Peter S HammermanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Henry YangCancer Science Institute of Singapore, National University of Singapore, Singapore.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1670-6513
Francine Garnache-OttouUniversité Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
H Phillip KoefflerCancer Science Institute of Singapore, National University of Singapore, Singapore.
Andrew A LaneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. andrew_lane@dfci.harvard.edu.ORCID 0000-0001-7380-0226
Dana-Farber Cancer Institute · USBroad Institute · USInserm · FRNational University of Singapore · SGBrigham and Women's Hospital · USInstitute for Biomedicine · ITMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USCedars-Sinai Medical Center · USJomo Kenyatta University of Agriculture and Technology · KEMassachusetts General Hospital · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTargeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)R37CA225191 · NCI · DANA-FARBER CANCER INST · PI LANE, ANDREW A · 2018 to 2024
$3.0MTargeting High-Risk Lymphoid NeoplasmsR35CA231958 · NCI · DANA-FARBER CANCER INST · PI WEINSTOCK, DAVID MARC · 2019 to 2021
$2.9MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS R35 CA231958NCI NIH HHS R37 CA225191
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of plasmacytoid dendritic cells (pDC). BPDCN occurs at least three times more frequently in men than in women, but the reasons for this sex bias are unknown. Here, studying genomics of primary BPDCN and modeling disease-associated mutations, we link acquired alterations in RNA splicing to abnormal pDC development and inflammatory response through Toll-like receptors. Loss-of-function mutations in
Indexed as
ApoptosisDendritic CellsFemaleGender IdentityHumansMaleMutationMyeloproliferative DisordersRibonucleoproteinsRibonucleoproteinsZRSR2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.